Table 4.
List of MSCs based clinical trials performed in different countries for the treatment of COVID-19 [83–85]
| Clinical Trial number | Title | Study phase | Status | Responsible Party | Country |
|---|---|---|---|---|---|
| NCT04299152 | Stem cell educator therapy treat the viral inflammation in COVID-19 | Phase 2 | Not yet recruiting | Tianhe Stem Cell Biotechnologies Inc. | United States of America |
| NCT04355728 | Umbilical cord-derived MSCs for COVID-19 patients with acute respiratory distress syndrome (ARDS). | Phase 1 and Phase 2 | Active, not recruiting | Camillo Ricordi, University of Miami | Miami, Florida, United States of America |
| NCT04313322 | Treatment of COVID-19 patients using Wharton’s jelly MSCs. | Phase 1 | Recruiting | Adeeb Al Zoubi, Stem Cell Arabia, | Aman, Jordon |
| NCT04315987 | Exploratory clinical study to assess the efficacy of NestaCell® MSCs to treat patients with severe COVID-19 pneumonia. | Phase 2 | Not yet recruiting | Azidus | São Paulo, Brazil |
| NCT04302519 | Clinical study of novel coronavirus induced severe pneumonia treated by dental pulp MSCs. | Early Phase 1 | Not yet recruiting | CAR-T (Shanghai) Biotechnology Co., Ltd. | China |
| NCT04288102 | Treatment with human umbilical cord-derived MSCs for severe coronavirus disease 2019 (COVID-19). | Phase 2 | Active, not Recruiting | Fu-Sheng Wang, Beijing 302 Hospital | Wuhan, Hubei, China |
| NCT04269525 | Umbilical cord (UC)-derived MSCs treatment for the 2019-novel Coronavirus (COV) pneumonia. | Phase 2 | Recruiting | ZhiYong Peng, Zhongnan Hospital | Wuhan, Hubei, China |
| NCT04276987 | A pilot clinical study on inhalation of MSCs exosomes treating severe novel coronavirus pneumonia. | Phase 1 | Enrolling by invitation | Ruijin Hospital | Shanghai, China |
| NCT04293692 | Therapy for pneumonia patients infected by 2019 novel coronavirus | Not applicable | Withdrawn | Puren hospital affiliated to Wuhan University of Science and Technology | Wuhan, Hubei, China |
| NCT04456361 | Use of MSCs in acute respiratory distress syndrome caused by COVID-19. | Early Phase 1 | Active, not recruiting | Instituto de Medicina Regenerativa | Tijuana, Baja California, Mexico |
| NCT04366323 | Phase I/II clinical trial to evaluate the safety and efficacy of allogenic adipose tissue-derived MSCs expanded in patients with severe COVID-19 pneumonia. |
Phase 1 Phase 2 |
Recruiting | Hospital Universitario de Jerez de la Frontera | Spain |